vimarsana.com

Ann Thorac News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Improving lung cancer surgery through novel computed tomography

This article from Thermo Scientific outlines how Amira software was used as a tool to perform computed tomography to improve lung cancer surgery.

Chao liuUnited statesHuike gaoEmily mageeJournal of international medical researchAmerican cancer societyThermo fisherThermo fisher amira softwareJining medical universityAmira softwareSponsored contentThermo fisher scientificThermo scientificInternational medicalCancer societyAccessed january

Roivios® announces final patient enrollment in feasibility trial for JuxtaFlow® Renal Assist Device (RAD)

ROSWELL, Ga., Dec. 4, 2023 /PRNewswire/ Roivios Ltd., a medical device company pioneering a revolutionary treatment to reduce poor surgical out.

Bielsko bialaSremska kamenicaUnited statesMilovan petrovicLazar velickiDimitrije jeremicJohn erbeyInstitute of cardiovascular diseasesPrnewswire roivios ltdInstitute for cardiovascular diseases dedinjeAcute kidney injuryJuxtaflow renal assist deviceCardiovascular diseasesProf dr milovan petrovicProf dr lazar velickiAmerican heart hospital

Sublobar Resection Should Be New Standard Care for Certain Patients With NSCLC

Sublobar resection is noninferior to a full lobectomy in patients with carefully staged cT1aN0 non-small cell lung cancer, new research suggests.

New yorkUnited statesNasserk altorkiHisashi sajiAstellas pharmaMerck sharpe dohmeBristol myers squibbChugai pharmaYork genome centerBoehringer ingelheimTakeda pharmaceutical companyJapan blood products organizationLung cancer study groupJanssen pharmaceuticalsSt marianna university school of medicineWeill cornell medicine

Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

/PRNewswire/ Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the.

United statesAlexanderi spiraCharlesm baumAmerican society of clinical oncologyVirginia cancer specialists research institutePrnewswire mirati therapeutics incDrug administrationMirati therapeutics incExchange commissionAccess programClinical oncologyAnnual meetingNon small cellClinical resultsEnabling studyBlinded independent central review

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer

United kingdomUnited statesNathalie meetzLevi garrawayEurope luRoche tecentriqSileia urechLoren kalmAnne marie bairdKarsten kleineEuropean lung cancer congressEuropean commissionWorld health organizationHead of global product developmentEuropean medicines agencyRoche group

vimarsana © 2020. All Rights Reserved.